Fruquintinib

HUTCHMED will unveil new clinical data at ESMO Asia (Dec 5‑7, 2025, Singapore) and ASH (Dec 6‑9, 2025, Orlando). Highlights include first‑in‑human results for the anti‑CD47 antibody HMPL‑A83, Phase II FRUSICA‑2 readouts of fruquintinib + sintilimab in second‑line renal cell carcinoma, Phase II data on surufatinib + camrelizumab + chemotherapy for metastatic pancreatic cancer, and the final Phase III analysis of sovleplenib (ESLIM‑01) in chronic primary immune thrombocytopenia. These disclosures mark key milestones for the company’s oncology and immune‑mediated pipelines.

HUTCHMED and Innovent Biologics announced the NMPA acceptance of a New Drug Application for fruquintinib and sintilimab combination therapy. This targets advanced renal cell carcinoma patients who failed prior tyrosine kinase inhibitor treatment. Based on positive FRUSICA-2 trial results, it met its primary endpoint of progression-free survival. The therapy may address the unmet needs for second-line treatment, with ongoing research to expand its applications and indications in immuno-oncology.